



MORVUS TECHNOLOGY RAISES £2.15M TO PROGRESS ITS PORTFOLIO OF ANTI-CANCER DRUGS

December 4th , 2009, Carmarthen. Morvus Technology Limited (“Morvus”), a UK-based pharmaceutical company focused on therapeutics for the oncology market, today announces it has completed a £2.15m fundraising round. Participation in the round was solely by private investors and Morvus will use the funds to advance and strengthen its portfolio of oncology drug candidates.

Phil Burke, the CEO of Morvus said: “I am delighted that we have been able to complete this substantial financing round in a very challenging economic climate. Since its formation Morvus has built a strong pipeline of product candidates and the funds raised in this round will enable us to progress these towards commercialisation.”

About Morvus Technology Ltd.

Morvus Technology is a privately-owned company engaged in the discovery, development and commercialisation of novel drugs for the oncology market. The Company was established in 2004 and has offices and laboratories near Carmarthen, South West Wales. Morvus has a broad portfolio of technology which is focused on disease areas for which there is a clear, unmet medical need.

CONTACT:

Dr Phil Burke
CEO
Morvus Technology Ltd
E: pburke@morvus.com
T: +44 (0) 1558 667 184